AR059327A1 - Monohidrato de rimonabant su procedimiento de preparacion y composiciones farmaceuticas que lo contienen - Google Patents

Monohidrato de rimonabant su procedimiento de preparacion y composiciones farmaceuticas que lo contienen

Info

Publication number
AR059327A1
AR059327A1 ARP070100477A ARP070100477A AR059327A1 AR 059327 A1 AR059327 A1 AR 059327A1 AR P070100477 A ARP070100477 A AR P070100477A AR P070100477 A ARP070100477 A AR P070100477A AR 059327 A1 AR059327 A1 AR 059327A1
Authority
AR
Argentina
Prior art keywords
rimonabant
monohidrate
pharmaceutical compositions
compositions containing
preparation procedure
Prior art date
Application number
ARP070100477A
Other languages
English (en)
Inventor
Olivier Monnier
Baptiste Fours
Helene Duplaa
Philippe Ochsenbein
Gerard Coquerel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37075667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059327(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR059327A1 publication Critical patent/AR059327A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 2: La forma cristalina del monohidrato de rimonabant segun la reivindicacion 1, caracterizada por un pico de fusion entre 95°C+- 5°C y 115°C+- 5°C.
ARP070100477A 2006-02-08 2007-02-06 Monohidrato de rimonabant su procedimiento de preparacion y composiciones farmaceuticas que lo contienen AR059327A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0601253A FR2897060B1 (fr) 2006-02-08 2006-02-08 Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
AR059327A1 true AR059327A1 (es) 2008-03-26

Family

ID=37075667

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100477A AR059327A1 (es) 2006-02-08 2007-02-06 Monohidrato de rimonabant su procedimiento de preparacion y composiciones farmaceuticas que lo contienen

Country Status (20)

Country Link
US (1) US20090048449A1 (es)
EP (1) EP1984341A1 (es)
JP (1) JP2009526025A (es)
KR (1) KR20080093042A (es)
CN (1) CN101405271A (es)
AR (1) AR059327A1 (es)
AU (1) AU2007213649A1 (es)
BR (1) BRPI0707711A2 (es)
CA (1) CA2641494A1 (es)
DO (1) DOP2007000023A (es)
EA (1) EA200870236A1 (es)
FR (1) FR2897060B1 (es)
GT (1) GT200700014A (es)
IL (1) IL192963A0 (es)
MA (1) MA30312B1 (es)
NO (1) NO20083521L (es)
TW (1) TW200804343A (es)
UY (1) UY30137A1 (es)
WO (1) WO2007090949A1 (es)
ZA (1) ZA200806713B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
WO2008056377A2 (en) * 2006-11-06 2008-05-15 Cadila Healthcare Limited Polymorphic forms of rimonabant
CN110922366B (zh) * 2014-12-08 2023-02-03 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
JP4746931B2 (ja) * 2005-07-22 2011-08-10 株式会社日立製作所 フラットディスプレイパネルモジュール及びフラットディスプレイ装置
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
WO2008035023A1 (en) * 2006-09-19 2008-03-27 Cipla Limited Polymorphs of rimonabant

Also Published As

Publication number Publication date
FR2897060A1 (fr) 2007-08-10
DOP2007000023A (es) 2008-02-15
ZA200806713B (en) 2009-10-28
WO2007090949A1 (fr) 2007-08-16
AU2007213649A1 (en) 2007-08-16
IL192963A0 (en) 2009-02-11
MA30312B1 (fr) 2009-04-01
CA2641494A1 (fr) 2007-08-16
EP1984341A1 (fr) 2008-10-29
US20090048449A1 (en) 2009-02-19
FR2897060B1 (fr) 2008-07-25
CN101405271A (zh) 2009-04-08
JP2009526025A (ja) 2009-07-16
KR20080093042A (ko) 2008-10-17
UY30137A1 (es) 2007-09-28
EA200870236A1 (ru) 2009-02-27
NO20083521L (no) 2008-10-24
GT200700014A (es) 2007-09-19
BRPI0707711A2 (pt) 2011-05-10
TW200804343A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
MX2008001799A (es) Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
HUE026549T2 (hu) 1-N-azacikloalkil-3-fenoxipropán pszichotróp gyógyszerek elõállítására alkalmas származékai
EP1879456A4 (en) PHARMACEUTICAL COMPOSITIONS WITH SYNCHRONIZED RELEASE OF SOLUBILIZING AGENT
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
WO2006096518A3 (en) Improved gacyclidine formulations
PL1948666T3 (pl) Inhibitory integrazy HIV
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
IL191907A0 (en) Azepinoindole derivatives as pharmaceutical agents
CU20060038A7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
NO20090175L (no) Stabile laquinimod sammensetninger
EP2044068A4 (en) 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS
CU20120002A7 (es) DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA
TW200942524A (en) Novel aminomethyl benzene derivatives
IL185197A0 (en) Ophthalmological pharmaceutical compositions
TW200942530A (en) Pyridine compounds
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EP1910363A4 (en) INHIBITORS OF HIV INTEGRASE
ZA201004031B (en) Dehydrohalagenation process for the preparation of intermediates useful in providing 6,6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds
EA201000039A1 (ru) Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль
EP1941896A4 (en) COMPOSITION CONTAINING A DIPEPTIDE FOR ORAL ADMINISTRATION
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2009008249A (es) Composicion farmaceutica que comprende derivado de camptotecina.
HU0500683D0 (en) New arylpiprazole salts for producing pharmaceutical composition
AR059327A1 (es) Monohidrato de rimonabant su procedimiento de preparacion y composiciones farmaceuticas que lo contienen
AR077915A1 (es) Forma cristalina de pemirolast

Legal Events

Date Code Title Description
FB Suspension of granting procedure